Academic collaboration Opportunity to expand partnerships with prestigious cancer centers (e.g., Memorial Sloan Kettering) leveraging Precipio's Bloodhound BCR::ABL1 assay and CLIA/CAP lab services to co-develop and validate diagnostic workflows for hematologic malignancies.

Clinical adoption Position Precipio as a turnkey solution integrating proprietary diagnostic products with its clinical laboratory services to hospitals and oncologist practices seeking improved diagnostic accuracy and streamlined lab workflows.

Financial momentum Leverage record quarterly revenue milestones and positive EBITDA/cash flow signals to target mid-market hospitals and independent labs upgrading from legacy platforms, offering scalable product bundles and favorable ROI narratives.

Security and trust Address data privacy concerns highlighted by recent breach news by emphasizing robust cybersecurity measures, compliance, and data protection services as a differentiator when selling to healthcare organizations with sensitive patient information.

Product roadmap Highlight ongoing product launches such as Quantitative BCR-ABL 2.0 and COVID-19 testing capabilities as selling points to laboratories aiming to diversify test menus, improve diagnostic capabilities, and expand revenue streams.